Mauro, Michael John

Publications

Sort by

Co-Author Network

selected publications

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC cancer. 2018 Academic Article GET IT
Times cited: 17
Running the marathon of chronic myeloid leukemia with no shoes (or without the right shoes)!. Cancer. 2017 Editorial Article GET IT
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017 Academic Article GET IT
Times cited: 80
Can any patients with chronic myeloid leukemia outside of a clinical trial have their tyrosine kinase inhibitor discontinued?. Current opinion in hematology. 2017 Information Resource GET IT
Times cited: 1
Chronic myeloid leukemia: Is it dusk or dawn?. Best practice & research. Clinical haematology. 2016 Editorial Article GET IT
Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management. Clinical lymphoma, myeloma & leukemia. 2016 Information Resource GET IT
Times cited: 34
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. The New England journal of medicine. 2016 Academic Article GET IT
Times cited: 218
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. American journal of hematology. 2016 Academic Article GET IT
Times cited: 73
Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia. Clinical lymphoma, myeloma & leukemia. 2016 Academic Article GET IT
Times cited: 9
Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study. Clinical lymphoma, myeloma & leukemia. 2016 Academic Article GET IT
Times cited: 29
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia. 2015 Academic Article GET IT
Times cited: 58
The role of observational studies in optimizing the clinical management of chronic myeloid leukemia. Therapeutic advances in hematology. 2015 Information Resource GET IT
Times cited: 22
Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System. American journal of hematology. 2015 Academic Article GET IT
Times cited: 38
Extending the reach of nilotinib in chronic myeloid leukemia. Haematologica. 2014 Editorial Article GET IT
Integrating current treatment options for TKI-resistant chronic myeloid leukemia. Clinical advances in hematology & oncology : H&O. 2014 Academic Article GET IT
Times cited: 1
The challenge of the 'C' in CML. Leukemia research. 2013 Editorial Article GET IT
Sequential therapy in chronic myelogenous leukemia: where do emerging therapies fit within current treatment regimens?. Clinical advances in hematology & oncology : H&O. 2013 Information Resource GET IT
Striving to achieve safe, permanent treatment discontinuation in chronic myeloid leukemia. Leukemia research. 2013 Information Resource GET IT
Times cited: 8
The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013 Academic Article GET IT
Times cited: 59
Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. British journal of haematology. 2013 Article GET IT
Times cited: 56
T315I, more or less, predicts for major molecular response: the devil is in the details!. Haematologica. 2013 Editorial Article GET IT
Times cited: 3
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. Cancer chemotherapy and pharmacology. 2013 Academic Article GET IT
Times cited: 22
Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib. American journal of hematology. 2013 Academic Article GET IT
Times cited: 48
Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013 Academic Article GET IT
Times cited: 151
Overcoming resistance in chronic myelogenous leukemia. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2013 Information Resource GET IT
Times cited: 1
Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. Leukemia & lymphoma. 2012 Information Resource GET IT
Times cited: 10
Ponatinib in refractory Philadelphia chromosome-positive leukemias. The New England journal of medicine. 2012 Academic Article GET IT
Times cited: 648
Current practices in the management of chronic myeloid leukemia. Clinical lymphoma, myeloma & leukemia. 2012 Academic Article GET IT
Times cited: 10
Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia. Clinical advances in hematology & oncology : H&O. 2012 Academic Article GET IT
Times cited: 5
Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood. 2011 Academic Article GET IT
Times cited: 55
Practical management of patients with chronic myeloid leukemia. Cancer. 2011 Information Resource GET IT
Times cited: 23
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications. Cancer. 2010 Information Resource GET IT
Times cited: 51
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood. 2009 Academic Article GET IT
Times cited: 107
Management of drug toxicities in chronic myeloid leukaemia. Best practice & research. Clinical haematology. 2009 Information Resource GET IT
Times cited: 35
Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood. 2009 Academic Article GET IT
Times cited: 71
Response dynamics in chronic-phase chronic myeloid leukemia. Clinical lymphoma & myeloma. 2009 Information Resource GET IT
Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Cancer control : journal of the Moffitt Cancer Center. 2009 Information Resource GET IT
Appropriate sequencing of tyrosine kinase inhibitors in chronic myelogenous leukemia: when to change? A perspective in 2009. Current opinion in hematology. 2009 Information Resource GET IT
Times cited: 6
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia. Leukemia. 2008 Article GET IT
Times cited: 27
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 107
Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors. Current treatment options in oncology. 2007 Information Resource GET IT
Times cited: 1
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia. 2007 Academic Article GET IT
Times cited: 71
Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used?. Mayo Clinic proceedings. 2006 Information Resource GET IT
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood. 2006 Academic Article GET IT
Times cited: 113
Defining and managing imatinib resistance. Hematology. American Society of Hematology. Education Program. 2006 Information Resource GET IT
Times cited: 74
Baseline disease risk and response to therapy in chronic myeloid leukemia: necessary predictive tools then and now. Haematologica. 2005 Article GET IT
Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. Mayo Clinic proceedings. 2005 Information Resource GET IT
Ph-positive and -negative myeloproliferative syndromes may co-exist. Leukemia. 2004 Article GET IT
Times cited: 7
Thienopyridine-linked thrombotic microangiopathy: association with endothelial cell apoptosis and activation of MAP kinase signalling cascades. British journal of haematology. 2004 Academic Article GET IT
Times cited: 32
Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood. 2003 Academic Article GET IT
Times cited: 99
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood. 2003 Academic Article GET IT
Times cited: 85
STI571 as a targeted therapy for CML. Cancer investigation. 2003 Information Resource GET IT
Times cited: 53
Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia. 2003 Academic Article GET IT
Times cited: 102
The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood. 2002 Academic Article GET IT
Times cited: 114
Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood. 2002 Academic Article GET IT
Times cited: 94
Recent advancements in the treatment of chronic myelogenous leukemia. Annual review of medicine. 2002 Information Resource GET IT
Times cited: 58
ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy. Cancer chemotherapy and pharmacology. 2001 Academic Article GET IT
Times cited: 27
STI571: a gene product-targeted therapy for leukemia. Current oncology reports. 2001 Information Resource GET IT
Times cited: 33
Chronic myelogenous leukemia. Current opinion in oncology. 2001 Information Resource GET IT
Times cited: 78
Role of transforming growth factor beta1 in microvascular endothelial cell apoptosis associated with thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome. American journal of hematology. 2001 Academic Article GET IT
Times cited: 17

more ...

less ...

Background

education and training

M.D., Dartmouth Medical School 1994
B.A., Dartmouth College 1990

Contact

full name

Michael John Mauro

VIVO Weill Cornell Medical College

Michael John Mauro Professor of Clinical Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name